Effects of mogamulizumab in adult T-cell leukemia/lymphoma in clinical practice

被引：18

作者：

Sekine, Masaaki ^{[1
]}

Kubuki, Yoko ^{[1
]}

Kameda, Takuro ^{[1
]}

Takeuchi, Masanori ^{[2
]}

Toyama, Takanori ^{[3
]}

Kawano, Noriaki ^{[4
]}

Maeda, Kouichi ^{[5
]}

Sato, Seiichi ^{[6
]}

Ishizaki, Junzo ^{[7
]}

Kawano, Hiroshi ^{[2
]}

Kamiunten, Ayako ^{[1
]}

Akizuki, Keiichi ^{[1
]}

Tahira, Yuki ^{[1
]}

Shimoda, Haruko ^{[1
]}

Shide, Kotaro ^{[1
]}

Hidaka, Tomonori ^{[1
]}

Kitanaka, Akira ^{[8
]}

Yamashita, Kiyoshi ^{[4
]}

Matsuoka, Hitoshi ^{[2
]}

Shimoda, Kazuya ^{[1
]}

机构：

[1] Univ Miyazaki, Dept Gastroenterol & Hematol, Fac Med, Miyazaki, Japan

[2] Koga Gen Hosp, Miyazaki, Japan

[3] Miyazaki Prefectural Nobeoka Hosp, Nobeoka, Japan

[4] Miyazaki Prefectural Miyazaki Hosp, Miyazaki, Japan

[5] Miyakonojo Med Ctr, Miyakonojo, Japan

[6] Fujimoto Genral Hosp, Miyakonojo, Japan

[7] Miyazaki Aisenkai Nichinan Hosp, Nichinan, Japan

[8] Kawasaki Med Sch, Dept Lab Med, Kurashiki, Okayama, Japan

来源：

EUROPEAN JOURNAL OF HAEMATOLOGY | 2017年 / 98卷 / 05期

关键词：

adult T-cell leukemia; lymphoma; antibody therapy; CC chemokine receptor 4; mogamulizumab; retrospective; LEUKEMIA-LYMPHOMA; PROGNOSTIC INDEX; ANTIBODY; CCR4; KW-0761;

D O I：

10.1111/ejh.12863

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

ObjectiveThe efficacy of mogamulizumab in adult T-cell leukemia/lymphoma (ATLL) was reported in a previous phase 2 study. Compared with patients in clinical trials, however, most patients in real-life settings have demonstrated worse outcomes. MethodWe retrospectively analyzed 96 patients with relapsed/refractory ATLL who received mogamulizumab treatment. ResultsRelapsed/refractory ATLL patients with a median age of 70years received a median of five courses of mogamulizumab. Hematologic toxicity and skin rash were the most common adverse events, and both were manageable. Of 96 patients, 87 were evaluable for efficacy. The overall response rate was 36%, and the median progression-free survival (PFS) and overall survival (OS) from the start of mogamulizumab therapy were 1.8 and 4.0months, respectively. Of the original 96 patients, only 25 fulfilled the inclusion criteria of the phase 2 study. Those who met the criteria demonstrated longer median PFS and OS durations of 2.7 and 8.5months, respectively. The median OS from diagnosis in relapsed/refractory ATLL patients receiving mogamulizumab was 12months, longer than the 5.8months in a historical cohort without mogamulizumab. ConclusionIn clinical practice, mogamulizumab exhibited antitumor activity in patients with relapsed/refractory ATLL, with an acceptable toxicity profile. Mogamulizumab therapy improved the OS of ATLL patients.

引用

页码：501 / 507

页数：7

共 19 条

[1] The chemokine receptor CCR4 in vascular recognition by cutaneous but not intestinal memory T cells [J].

Campbell, JJ ;

Haraldsen, G ;

Pan, J ;

Rottman, J ;

Qin, S ;

Ponath, P ;

Andrew, DP ;

Warnke, R ;

Ruffing, N ;

Kassam, N ;

Wu, L ;

Butcher, EC .

NATURE, 1999, 400 (6746) :776-780

[2] Japan Clinical Oncology Group (JCOG) prognostic index and characterization of long-term survivors of aggressive adult T-cell leukaemia-lymphoma (JCOG0902A) [J].

Fukushima, Takuya ;

Nomura, Shogo ;

Shimoyama, Masanori ;

Shibata, Taro ;

Imaizumi, Yoshitaka ;

Moriuchi, Yoshiyuki ;

Tomoyose, Takeaki ;

Uozumi, Kimiharu ;

Kobayashi, Yukio ;

Fukushima, Noriyasu ;

Utsunomiya, Atae ;

Tara, Mitsutoshi ;

Nosaka, Kisato ;

Hidaka, Michihiro ;

Uike, Naokuni ;

Yoshida, Shinichiro ;

Tamura, Kazuo ;

Ishitsuka, Kenji ;

Kurosawa, Mitsutoshi ;

Nakata, Masanobu ;

Fukuda, Haruhiko ;

Hotta, Tomomitsu ;

Tobinai, Kensei ;

Tsukasaki, Kunihiro .

BRITISH JOURNAL OF HAEMATOLOGY, 2014, 166 (05) :739-748

[3]

Institute NC, COMM TERM CRIT ADV E

[4] Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: a randomized phase II study [J].

Ishida, Takashi ;

Jo, Tatsuro ;

Takemoto, Shigeki ;

Suzushima, Hitoshi ;

Uozumi, Kimiharu ;

Yamamoto, Kazuhito ;

Uike, Naokuni ;

Saburi, Yoshio ;

Nosaka, Kisato ;

Utsunomiya, Atae ;

Tobinai, Kensei ;

Fujiwara, Hiroshi ;

Ishitsuka, Kenji ;

Yoshida, Shinichiro ;

Taira, Naoya ;

Moriuchi, Yukiyoshi ;

Imada, Kazunori ;

Miyamoto, Toshihiro ;

Akinaga, Shiro ;

Tomonaga, Masao ;

Ueda, Ryuzo .

BRITISH JOURNAL OF HAEMATOLOGY, 2015, 169 (05) :672-682

[5] Defucosylated Anti-CCR4 Monoclonal Antibody (KW-0761) for Relapsed Adult T-Cell Leukemia-Lymphoma: A Multicenter Phase II Study [J].

Ishida, Takashi ;

Joh, Tatsuro ;

Uike, Naokuni ;

Yamamoto, Kazuhito ;

Utsunomiya, Atae ;

Yoshida, Shinichiro ;

Saburi, Yoshio ;

Miyamoto, Toshihiro ;

Takemoto, Shigeki ;

Suzushima, Hitoshi ;

Tsukasaki, Kunihiro ;

Nosaka, Kisato ;

Fujiwara, Hiroshi ;

Ishitsuka, Kenji ;

Inagaki, Hiroshi ;

Ogura, Michinori ;

Akinaga, Shiro ;

Tomonaga, Masao ;

Tobinai, Kensei ;

Ueda, Ryuzo .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (08) :837-842

[6] Defucosylated anti-CCR4 monoclonal antibody exercises potent ADCC-mediated antitumor effect in the novel tumor-bearing humanized NOD/Shi-scid, IL-2Rγnull mouse model [J].

Ito, Asahi ;

Ishida, Takashi ;

Yano, Hiroki ;

Inagaki, Atsushi ;

Suzuki, Susumu ;

Sato, Fumihiko ;

Takino, Hisashi ;

Mori, Fumiko ;

Ri, Masaki ;

Kusumoto, Shigeru ;

Komatsu, Hirokazu ;

Iida, Shinsuke ;

Inagaki, Hiroshi ;

Ueda, Ryuzo .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2009, 58 (08) :1195-1206

[7]

Iyama S, 2016, CLIN LYMPHOMA MYELOM, V17, P31

[8] Prognostic Index for Acute- and Lymphoma-Type Adult T-Cell Leukemia/Lymphoma [J].

Katsuya, Hiroo ;

Yamanaka, Takeharu ;

Ishitsuka, Kenji ;

Utsunomiya, Atae ;

Sasaki, Hidenori ;

Hanada, Shuichi ;

Eto, Tetsuya ;

Moriuchi, Yukiyoshi ;

Saburi, Yoshio ;

Miyahara, Masaharu ;

Sueoka, Eisaburo ;

Uike, Naokuni ;

Yoshida, Shinichiro ;

Yamashita, Kiyoshi ;

Tsukasaki, Kunihiro ;

Suzushima, Hitoshi ;

Ohno, Yuju ;

Matsuoka, Hitoshi ;

Jo, Tatsuro ;

Suzumiya, Junji ;

Tamura, Kazuo .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (14) :1635-1640

[9] Clinical Impact of a Humanized CCR4 Antibody (Mogamulizumab) in 14 Patients with Aggressive Adult T-cell Leukemia-lymphoma Treated at a Single Institution During a Three-year Period (2012-2014) [J].

Kawano, Noriaki ;

Kuriyama, Takuro ;

Sonoda, Koh-Hei ;

Yoshida, Shuro ;

Yamashita, Kiyoshi ;

Ochiai, Hidenobu ;

Shimoda, Kazuya ;

Ishikawa, Fumihiko ;

Ueda, Akira ;

Kikuchi, Ikuo .

INTERNAL MEDICINE, 2016, 55 (11) :1439-1445

[10] Acute myeloid leukemia in clinical practice: a retrospective population-based cohort study in Miyazaki Prefecture, Japan [J].

Matsunaga, Takuya ;

Yamashita, Kiyoshi ;

Kubuki, Yoko ;

Toyama, Takanori ;

Imataki, Osamu ;

Maeda, Kouichi ;

Kawano, Noriaki ;

Satou, Seiichi ;

Kawano, Hiroshi ;

Ishizaki, Junzo ;

Yoshida, Shuro ;

Kameda, Takuro ;

Sasaki, Tadashi ;

Sekine, Masaaki ;

Kamiunten, Ayako ;

Taniguchi, Yasuhiro ;

Hidaka, Tomonori ;

Katayose, Keiko ;

K-Shimoda, Haruko ;

Shide, Kotaro ;

Yamamoto, Shojiro ;

Moritake, Hiroshi ;

Nunoi, Hiroyuki ;

Makino, Shigeyoshi ;

Kitanaka, Akira ;

Matsuoka, Hitoshi ;

Shimoda, Kazuya .

INTERNATIONAL JOURNAL OF HEMATOLOGY, 2012, 96 (03) :342-349

← 1 2 →